髓系恶性肿瘤中的剪接因子突变
本文综述了2011年发现的RNA剪接机器相关驱动突变在血液肿瘤中的地位,指出剪接因子突变是MDS等髓系肿瘤最常见遗传病变之一,已纳入疾病分类和预后模型,但其克隆选择机制和基因型-表型关联仍待阐明。
要点
- 剪接因子突变是MDS等髓系肿瘤高频遗传病变,异常RNA剪接为关键致病通路。
- 剪接因子突变已纳入 contemporary 疾病分类与预后模型,具强基因型-表型关联。
- 共突变、克隆结构、衰老和造血微环境修饰疾病表达,机制与靶向治疗待突破。
核心结论
- 剪接因子突变是髓系肿瘤的重要驱动事件,异常RNA剪接成为主要致病通路。
研究设计与样本
- 综述性文章,总结2011年以来剪接因子突变在血液肿瘤中的研究发现。
主要发现
- 剪接因子突变是MDS和其他发育异常性髓系肿瘤中最常见的遗传病变之一。
- 剪接因子突变对RNA剪接具有突变特异性效应,并呈现强基因型-表型关联。
关键数值与推荐
- 剪接因子突变已被纳入当代疾病分类和预后模型。
临床怎么用
- 剪接因子突变可用于髓系肿瘤的分类和预后评估。
局限性
- 剪接因子突变的正向克隆选择机制和基因型-表型关联的机制仍不清楚。
- 共突变、克隆结构、衰老和造血微环境作为疾病表达的重要修饰因素尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discovery of recurrent somatic mutations affecting the RNA splicing machinery in 2011 revealed an unexpected class of driver mutations in hematologic malignancies. Remarkably, splicing factor (SF) mutations have emerged as some of the most frequent genetic lesions in myelodysplastic syndromes (MDS) and other dysplastic myeloid neoplasms, establishing aberrant RNA splicing as a major pathogenetic pathway in myeloid neoplasia. Subsequent studies have delineated their mutation-specific effects on RNA splicing and established their strong genotype-phenotype associations; consequently, SF mutations are now incorporated into contemporary disease classification and prognostic models. However, the mechanisms underlying their positive clonal selection and striking genotype-phenotype associations remain poorly understood, with co-mutations, clonal architecture, aging, and the hematopoietic microenvironment acting as important modifiers of disease expression. Elucidating how SF mutations interact with these modifiers to shape clonal fitness and disease phenotype remains a key challenge, while translating these biological insights into effective therapies represents the ultimate clinical goal.
引用
- Cazzola M, Ogawa S. Splicing Factor Mutations in Myeloid Malignancies. Blood. 2026. PMID: 42932249. doi:10.1182/blood.2026035568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。